Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 289

Posts Tagged ‘drug’

Trials of a vaccine and new drug raise hope of beating covid-19

Posted by fidest press agency su venerdì, 24 luglio 2020

IN EARLY JANUARY researchers at Oxford University started work on a vaccine for covid-19. At that time the illness was a tiny outbreak without a proper name. Six months on, with more than 600,000 people dead, the Oxford team is leading a race to develop a vaccine that could halt the pandemic. The vaccine has been raced into production around the world by AstraZeneca, a British-Swedish drug company, and billions of doses are planned. But two key questions remain: is it safe and does it work? The first glimmers of the answers have just arrived, with the publication in the Lancet on July 20th of a paper about a trial of the Oxford vaccine, which began in April and involved 1,000 volunteers.According to Adrian Hill, director of Oxford’s Jenner Institute and one of the authors of the paper, the new vaccine stimulated a strong immune response and appears to be well tolerated and safe. It generated both antibodies and “an excellent” T-cell response. Antibodies and T-cells are the two principal arms of the immune system. The former recognise, lock onto and disable pathogens. The latter recognise and kill infected body cells, to stop viruses reproducing inside them. Dr Hill says that the antibody levels seen in the trial are similar to those observed in natural infections and that the T-cell responses are “very high”. They are also, he says, “clearly better” than those from another vaccine being developed by Moderna, an American biotechnology firm. (font: The Economist)

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Rydapt Insight Report, 2019

Posted by fidest press agency su domenica, 29 dicembre 2019

Rydapt – Drug Insight, 2019 report provides comprehensive information of the drug, Rydapt. It includes drugs overview, Rydapt mechanism of action, clinical trials, regulatory milestones, deals & Rydapt’s partnerships. It further provides Rydapt`s patents (US & EU)* and its API manufacturers details in the United States, Europe, China and India.It also features the historical and forecasted Rydapt sales till 2021. The report also throws light on Rydapt market competition and emerging therapies in the same space as Rydapt. Rydapt SWOT analysis is also featured.
A comprehensive Rydapt overview including product description, regulatory milestones, clinical trials, deals and partnerships, have been elaborated in this report
Rydapt Patent information in United States (US) and Europe (EU) has been highlighted
Rydapt API manufacturers in United States, Europe, China and India
The report contains historical and forecasted Rydapt sales till 2021
Comprehensive coverage of the emerging therapies (Phase III) in the space where Rydapt operates including their product description, research and development activities, collaborations and licensing deals, drug mechanism and chemical information The report also features the Rydapt SWOT analysis

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University’s Oxford Drug Discovery Institute

Posted by fidest press agency su venerdì, 25 ottobre 2019

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it will collaborate with Oxford University’s Oxford Drug Discovery Institute (ODDI) to use Bicycle® technology for the development of novel therapeutics for dementia. This expands upon the collaboration between Bicycle and the Dementia Discovery Fund, or DDF, a specialized venture capital fund focused on discovering and developing novel therapies for dementia, announced in May.
Under the terms of the agreement, Bicycle will use its novel and proprietary screening platform to identify Bicycles that bind to clinically validated dementia targets. ODDI, with its expertise in CNS disease, will then profile these Bicycles in a range of target-specific and disease-focused assays to determine their therapeutic potential. If promising lead compounds are identified, Bicycle will have rights to the development of the resulting intellectual property and, with DDF, will have the option to jointly establish a new company to develop those compounds.
“This collaboration is a natural extension of ODDI’s focus on novel targets in the dementia therapeutic area,” said Dr. John Davis, Chief Scientific Officer of ODDI. “As one of three institutes within the Alzheimer’s Research UK Drug Discovery Alliance, we understand the critical difference that collaboration between academia and industry can make in our efforts to accelerate drug discovery to bring new modalities into development. Bicycle’s platform has demonstrated the potential to deliver novel, selective and potent binders to a broad range of diverse targets, for many of which traditional small molecule approaches have not been successful. We are excited to be collaborators in this important drug discovery project.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Drug Discovery Collaboration for Multiple Therapeutic Areas

Posted by fidest press agency su domenica, 15 settembre 2019

Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and Atomwise, Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas. Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success and compress timelines for drug discovery and clinical development.
Atomwise’s world-class AI platform for structure-based drug design will direct hit discovery, hit-to-lead selection, and lead optimization efforts. Hansoh Pharma will contribute its capabilities in biological assays and medicinal chemistry, as well as lead subsequent preclinical and clinical development activities.Under the terms of the collaboration, Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Based on historical average revenues for small molecule drugs, the total potential value of the deal to Atomwise with success in all projects could be in excess of blockbuster potential. Hansoh Pharma will receive rights for development and commercialization in all fields and geographies.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Posted by fidest press agency su giovedì, 5 settembre 2019

LÖRRACH, Germany and SAINT-LOUIS, France, (GLOBE NEWSWIRE) Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant infections, today announced four upcoming presentations at the ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, taking place September 3-6 in Boston, MA at the Boston Park Plaza. The company and its collaborators will deliver presentations on its lead drug enmetazobactam (formerly AAI101), a potent extended-spectrum β-lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime is currently in late stage of a global Phase 3 development for the treatment of complicated urinary tract infections, including acute pyelonephritis, by Gram-negative bacteria.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

The “Cardiovascular Drug Delivery – Technologies, Markets & Companies”

Posted by fidest press agency su giovedì, 15 agosto 2019

The cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.
Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems.Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.Cell-selective targeted drug delivery has emerged as one of the most significant areas of biomedical engineering research, to optimize the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. These concepts have been applied to targeted drug delivery to the cardiovascular system. Devices for drug delivery to the cardiovascular system are also described.Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions. A full chapter is devoted to drug-eluting stents as a treatment for restenosis following stenting of coronary arteries. Fifteen companies are involved in drug-eluting stents.Selected 82 companies that either develop technologies for drug delivery to the cardiovascular system or products using these technologies are profiled and 80 collaborations between companies are tabulated. The bibliography includes 200 selected references from recent literature on this topic. The report is supplemented with 31 tables and 9 figures.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Rite Aid Foundation Launches New Prescription Drug Safety Initiative in Harrisburg-Area High Schools

Posted by fidest press agency su lunedì, 18 marzo 2019

In an effort to help address adolescent drug abuse and misuse in Pennsylvania, The Rite Aid Foundation is bringing the Prescription Drug Safety program, an innovative digital course about prescription drug abuse prevention, to Harrisburg-area high schools.The program, developed by EVERFI, the nation’s leading education technology innovator used in one in seven schools nationwide, will be made available to high schools in Cumberland, Dauphin, and York counties at no cost. Representatives of The Rite Aid Foundation, Executive Deputy Attorney General for Public Engagement Rob Reed and Harrisburg School District officials announced the launch of the new program during a press conference and demonstration at Harrisburg High School SciTech Campus.
The Prescription Drug Safety program uses an evidence-based, public health approach to empower high school students with the skills and knowledge they need to make safe and healthy decisions about prescription drugs. Through interactive scenarios and self-guided activities, students learn the facts about drugs, how to properly use and dispose of them, and how to step in when faced with a situation involving misuse. The course is aligned with the Centers for Disease Control and Prevention’s National Health Education Standards and state academic standards.Pennsylvania is one of the states hardest hit by prescription drug abuse and the opioid epidemic. According to the Centers for Disease Control and Prevention, Pennsylvania is among the top five states with the highest rates of opioid-related deaths, with 5,456 deaths being attributed to opioid drug overdose in 2017, per the Drug Enforcement Administration.
The School District of the City of Harrisburg is committed to providing a rigorous and relevant education to all students in an innovative, supportive and culturally responsive learning environment that fosters high expectations, and data driven, standards aligned instruction provided by committed, highly qualified educators. Through collaborative partnerships, and strong parent and community engagement, we aim to empower all students to become academic achievers and lifelong learners who are motivated and prepared to compete and succeed beyond high school graduation in 21st Century global markets.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

3rd Oral Drug Formulation Innovations: 2-Day Summit (Philadelphia, PA, United States

Posted by fidest press agency su sabato, 15 dicembre 2018

The “3rd Oral Drug Formulation Innovations” conference has been added to ResearchAndMarkets.com’s offering. The 3rd Annual Oral Drug Formulation Innovations Summit will showcase the industry’s latest formulation and delivery technologies for enhancing solubility and maximizing bioavailability.Learn directly from leading global formulation experts in both industry and academia on how to effectively develop poorly soluble drugs into scientifically unique, compliant, patient-centric formulations.Additionally, learn innovative strategies to significantly reduce product development timelines, brush up on the latest regulatory requirements and learn multiple innovative strategies to optimize and enhance your product portfolio.Leading Session Topics and Takeaways Include Breakthrough innovations in the next generation of drug products: A new thinking for formulation design
Creating next generation products: Evaluating innovations in oral drug formulation and delivery technologies Beyond the pill: Addressing future patient needs through the importance of pharmaceutical profiling. Effective formulation development strategies for improving oral bioavailability of poorly water-soluble drugs. Characterization of amorphous materials to advance product development. Spray-dried dispersion formulations in suspensions and solid dosage forms. Combining In-Vivo animal models with physiologically-based PBPK modeling.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

DEA National Prescription Drug Take-Back Day Set for April 28

Posted by fidest press agency su mercoledì, 25 aprile 2018

Count It! Lock It! Drop It!® (CLD) is encouraging Tennesseans to participate in the U.S. Drug Enforcement Administration’s National Prescription Drug Take-Back Day on Saturday, April 28. More than 150 take-back events will be held across the state from 10 a.m. to 2 p.m., when residents will have the opportunity to safely dispose of their unneeded or expired medications.
To help maintain record-setting numbers, community members are encouraged to stop by their nearest take-back location to drop off their unused or old medications, especially pain relievers and other prescription drugs. Pharmacists and law enforcement officers will be on hand to accept the medications and safely dispose of them, no questions asked.“Count It! Lock It! Drop It!® is a comprehensive community initiative funded by the BlueCross BlueShield of Tennessee Health Foundation that is focused on three easy steps anyone can take to prevent others from accessing their drugs: Count their pills, keep them locked up, and safely dispose of them at a take-back event or in a permanent drop box,” said Kristina Clark, project manager of the initiative. “CLD will be hosting a number of take-back locations to make it as easy and convenient as possible for people to rid their homes of medications they no longer use or need.” “Fifty-three percent of Americans who use prescription drugs recreationally got them from a friend or relative, according to the Substance Abuse and Mental Health Services Administration. A survey conducted for BlueCross BlueShield of Tennessee in 2016 also found that 64 percent of Tennesseans know someone who has become addicted to prescription pain medication,” said Dr. Andrea Willis, senior vice president and chief medical officer at BlueCross BlueShield of Tennessee. “National Prescription Drug Take-Back Days are a safe and easy way to protect your loved ones and to get these drugs out of your home.” Take-back events in Tennessee can be found at http://countitlockitdropit.org/drop-box-finder/. According to the DEA, Tennessee collected 54,294 pounds of medications statewide during two Take-Back Days in 2017. If you can’t make it to a take-back event, visit http://www.countitlockitdropit.org to find a drop box in your community. Drop boxes are available in all 95 Tennessee counties.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme

Posted by fidest press agency su mercoledì, 4 aprile 2018

PharmAbcine Inc., a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications, announced today that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its leading clinical compound TTAC-0001 for “treatment of Glioblastoma Multiforme.” “We are very pleased with this Orphan Drug Designation from FDA for TTAC-0001 for GBM treatment since we have been preparing for clinical studies of TTAC-0001 plus KEYTRUDA® (pembrolizumab) combo therapy for recurrent GBM in addition to TTAC-0001 mono therapy for recurrent GBM progressed after bevacizumab treatment. It will accelerate the progress of TTAC-0001 to provide clinical benefit in the treatment of GBM,” said Dr. Jin-San Yoo, president and chief executive officer of PharmAbcine, Inc.The FDA Office of Orphan Products Development grants Orphan Drug Designation to investigational drugs and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. Orphan drug status is intended to facilitate drug development for rare diseases and may provide several benefits to drug developers, including seven years of market exclusivity upon regulatory product approval, exemptions from certain FDA application fees, and tax credits for qualified clinical trials costs.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Blue Oak and PsychoGenics Announce a Drug Discovery Partnership

Posted by fidest press agency su mercoledì, 6 dicembre 2017

molecola epatite1Blue Oak Pharmaceuticals, Inc. (Blue Oak) and PGI Drug Discovery LLC (PsychoGenics), today announced that they have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions.Under the terms of the agreement, PsychoGenics is providing access to its powerful phenotypic discovery platforms, including its SmartCube® system and machine learning expertise, for unbiased discovery of novel therapeutics for brain disorders identified from the Blue Oak library of privileged chemotypes. The PsychoGenics technology platforms combine broad in vivo behavioral expertise with developments in robotics, computer vision, and bioinformatics to evaluate drug candidates for potential utility across the spectrum of CNS disease indications.“We are excited to have the opportunity to once again work with Drs. Tom Large and Kerry Spear, founders of Blue Oak. We have worked productively together at Sunovion in the past and have every confidence we can again discover first-in-class drugs and ultimately deliver much needed treatments to patients with severely disabling psychiatric conditions” remarked Emer Leahy, Ph.D., PsychoGenics’ President & Chief Executive Officer.“We have a strong, 10-year relationship with Dr. Emer Leahy and PsychoGenics that has validated our systems neurobiology paradigm for discovering clinical molecules with mechanisms-of-action distinct from existing drugs. We are confident that combining PGI’s deep behavioral profiling with Blue Oak’s privileged chemotypes and brain imaging biomarkers will yield the new therapies that have eluded the industry for several decades” said Tom Large, Ph.D., Blue Oak’s President and Chief Executive Officer.
By eliminating human bias and applying machine learning to high dimensional behavioral data, PsychoGenics together with its partners, have been instrumental in phenotypically identifying treatments with novel mechanisms-of-action. This includes an investigational psychotropic agent that is being studied in Phase II clinical trials as a treatment for patients with schizophrenia and for Parkinson’s disease psychosis.Blue Oak was founded on the concept that the next generation of drugs for brain disorders will be discovered by modulating brain circuitry, the most relevant “target” for many CNS diseases. Blue Oak’s proprietary chemistry platform is designed to engage brain circuits through polypharmacology rather than individual molecular targets, which is a key feature of most approved drugs for brain disorders. Integration with brain imaging and translational medicine biomarkers allows for the rapid optimization of clinical leads and Phase 1 clinical proof-of-principle studies.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor Jiandong Jiang

Posted by fidest press agency su martedì, 14 novembre 2017

pechinoPechino. Agilent Technologies Inc. (NYSE:A) today announced that Professor Jiandong Jiang has received an Agilent Thought Leader Award in support of his studies on cancer stem cells differentiation induced by natural products.“Cancer is a chronic disease generated by multiple factors. Our research is focused on the treatment of cancers with new concepts or principles, using cutting-edge techniques,” said Professor Jiang.Professor Jiang is director of the Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) in Beijing, China. He is also the vice-chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA). Professor Jiang’s research focuses on antimicrobial drugs, including viruses and bacteria, anticancer drugs, and the development of treatments for metabolic syndrome. The Agilent Thought Leader Award will enable Professor Jiang’s team to implement metabolite flux analyses, metabolism analyses, and integrated biology approaches to characterize the anti-tumor activity of natural products. In addition to Agilent mass spectrometry solutions, Professor Jiang’s lab will also make extensive use of Agilent Seahorse XF technology, and Agilent MassHunter and VistaFlux software. The project will also include a collaboration with Professor Wenbin Li from the Beijing Shijitan Hospital, Capital Medical University to perform clinical related research.“Agilent is proud to continue its support of cancer research with the use of our mass spectrometry systems, bioinformatics software, and metabolic analysis tools to facilitate the identification and characterization of cancer drugs,” said Victor Chan, Agilent vice president, and general manager of Laboratory Solutions for Agilent Greater China. Chan is the executive sponsor of this award.The IMM supports research and discovery of innovative drugs useful in treating or preventing human diseases. This work is done via creative multidisciplinary research based on Chinese herbal medicine and natural product research, along with the adoption of modern medical, and pharmaceutical theories and technologies.The Agilent Thought Leader Award promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and applied chemical markets. Information about previous award recipients is available on the Agilent Thought Leader Award webpage.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

La Food and Drug Administration (FDA) statunitense ha approvato idarucizumab

Posted by fidest press agency su mercoledì, 21 ottobre 2015

Boehringer Ingelheim, Germania. Boehringer Ingelheim GmbH comunica che la Food and Drug Administration (FDA) statunitense ha approvato idarucizumab, per l’uso in pazienti trattati con dabigatran etexilato, che necessitano di un’inattivazione dell’effetto anticoagulante, in caso di interventi chirurgici d’emergenza o procedure d’urgenza, oppure in caso di sanguinamento non controllato che possa mettere a rischio la vita del paziente.
L’FDA ha concesso a idarucizumab la designazione di Breakthrough Therapy con una “Priority Review”. Il farmaco è stato approvato con procedura accelerata. Il dossier della richiesta di autorizzazione ha incluso i risultati di studi su volontari sani e i risultati dell’analisi intermedia dello studio clinico RE-VERSE AD™ (NCT 02104947). In questi studi, l’inattivazione dell’effetto anticoagulante di dabigatran realizzata da idarucizumab si è vista immediatamente, a pochi minuti dalla somministrazione di 5 grammi del farmaco. Inoltre, non è stato osservato alcun effetto pro-coagulante dopo la somministrazione di idarucizumab.“L’arrivo dei nuovi anticoagulanti orali (NAO) ha segnato un progresso importante nella terapia anticoagulante. Benché esistano strategie generali per la gestione di sanguinamenti in caso di terapia con essi, sino ad oggi non era disponibile alcun farmaco che inattivasse in maniera immediata e specifica il loro effetto anticoagulante, in quelle rare situazioni di emergenza in cui la rapidità d’azione è importante, quali ad esempio un sanguinamento che mette a rischio la vita del paziente o la necessità di procedere rapidamente a un’operazione chirurgica o altro intervento” ha dichiarato il Dottor Charles Pollack, Professore di Medicina d’Emergenza-Urgenza, Sidney Kimmel Medical College, Università Thomas Jefferson di Philadelphia, USA, e Principale Sperimentatore dello studio RE-VERSE AD™. “L’avere ora a disposizione idarucizumab significa disporre di una soluzione unica per inattivare l’azione anticoagulante in pazienti che assumono dabigatran”.
Boehringer Ingelheim è impegnata per rendere disponibile idarucizumab quanto più ampiamente possibile. Il farmaco è attualmente in fase d’esame da parte di diverse autorità regolatorie, compresa la canadese Health Canada. Sono in corso ulteriori richieste di autorizzazione del farmaco alle autorità regolatorie di altri paesi.
Idarucizumab è un frammento di anticorpo umanizzato, o Fab, sviluppato come farmaco specifico per inattivare l’effetto di dabigatran. Idarucizumab si lega in maniera specifica esclusivamente alle molecole di dabigatran, neutralizzandone l’effetto anticoagulante senza interferire con la cascata della coagulazione. Idarucizumab è approvato negli Stati Uniti dove è indicato per l’impiego in pazienti trattati con dabigatran, che necessitano un’inattivazione dell’effetto anticoagulante dello stesso in caso di:
• interventi chirurgici d’emergenza/procedure urgenti
• sanguinamento non controllato o che possa mettere a rischio la vita del paziente
In altri paesi idarucizumab è attualmente in fase d’esame da parte delle autorità regolatorie o sono in corso gli inoltri delle richieste di registrazione. Idarucizumab è l’unico farmaco che svolge un’azione di inattivazione specifica dell’effetto di un NAO a essere in fase d’esame da parte delle autorità regolatorie. Boehringer Ingelheim intende inoltrare le richieste di autorizzazione all’immissione in commercio per idarucizumab in tutti i paesi in cui dabigatran è approvato.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

To combat drug resistance

Posted by fidest press agency su domenica, 3 aprile 2011

Geneva Tuesday, 5 April 2011, 2pm-3pm (Geneva time)  Salle de presse III, Palais des Nations, Geneva Drug resistance – also known as antimicrobial resistance – is becoming more dangerous. Urgent and consolidated efforts are needed if the world is to avoid regressing to the pre-antibiotic era.    Dr Hiroki Nakatani, Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases, WHO Dr Keiji Fukuda, Assistant Director-General, Health Security and the Environment, WHO Dr Mario Raviglione, Director, Stop TB Department, WHO (Moderator) Ms Christy Feig, Director of Communications, WHO For further information on World Health Day, please go to:  http://www.who.int/world-health-day/2011/en/index.html

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »